157 related articles for article (PubMed ID: 38211652)
1. IKZF4/NONO-RAB11FIP3 axis promotes immune evasion in gastric cancer via facilitating PD-L1 endosome recycling.
Weng N; Zhou C; Zhou Y; Zhong Y; Jia Z; Rao X; Qiu H; Zeng G; Jin X; Zhang J; Zhuang Z; Liang Z; Deng Y; Li Q; Yang S; Luo H; Wang H; Wu X
Cancer Lett; 2024 Mar; 584():216618. PubMed ID: 38211652
[TBL] [Abstract][Full Text] [Related]
2. Cancer-Associated Fibroblast-Derived IL-8 Upregulates PD-L1 Expression in Gastric Cancer Through the NF-κB Pathway.
Lou M; Iwatsuki M; Wu X; Zhang W; Matsumoto C; Baba H
Ann Surg Oncol; 2024 May; 31(5):2983-2995. PubMed ID: 38006530
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activator inhibitor-1 promotes immune evasion in tumors by facilitating the expression of programmed cell death-ligand 1.
Ibrahim AA; Fujimura T; Uno T; Terada T; Hirano KI; Hosokawa H; Ohta A; Miyata T; Ando K; Yahata T
Front Immunol; 2024; 15():1365894. PubMed ID: 38779680
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of DAPK1-mediated inhibition of IKKβ/CSN5/PD-L1 axis enhances natural killer cell killing ability and inhibits tumor immune evasion in gastric cancer.
Guo Z; Zhou C; Zhou L; Wang Z; Zhu X; Mu X
Cell Immunol; 2022 Feb; 372():104469. PubMed ID: 35114597
[TBL] [Abstract][Full Text] [Related]
5. Protein Kinase STK24 Promotes Tumor Immune Evasion via the AKT-PD-L1 Axis.
Wang N; Jiang Y; Li M; Wang H; Pan J; Tang Y; Xie S; Xu Y; Li X; Zhou X; Xu P; Lin W; Wang X
Adv Sci (Weinh); 2024 Mar; 11(12):e2304342. PubMed ID: 38229183
[TBL] [Abstract][Full Text] [Related]
6. Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy.
Jiang Y; Hong K; Zhao Y; Xu K
Front Immunol; 2023; 14():1228200. PubMed ID: 37415977
[TBL] [Abstract][Full Text] [Related]
7. Pharmaceutical targeting of OTUB2 sensitizes tumors to cytotoxic T cells via degradation of PD-L1.
Ren W; Xu Z; Chang Y; Ju F; Wu H; Liang Z; Zhao M; Wang N; Lin Y; Xu C; Chen S; Rao Y; Lin C; Yang J; Liu P; Zhang J; Huang C; Xia N
Nat Commun; 2024 Jan; 15(1):9. PubMed ID: 38167274
[TBL] [Abstract][Full Text] [Related]
8. Benzosceptrin C induces lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting DHHC3.
Wang Q; Wang J; Yu D; Zhang Q; Hu H; Xu M; Zhang H; Tian S; Zheng G; Lu D; Hu J; Guo M; Cai M; Geng X; Zhang Y; Xia J; Zhang X; Li A; Liu S; Zhang W
Cell Rep Med; 2024 Feb; 5(2):101357. PubMed ID: 38237597
[TBL] [Abstract][Full Text] [Related]
9. Reciprocal inhibition between TP63 and STAT1 regulates anti-tumor immune response through interferon-γ signaling in squamous cancer.
Jiang Y; Zheng Y; Zhang YW; Kong S; Dong J; Wang F; Ziman B; Gery S; Hao JJ; Zhou D; Zhou J; Ho AS; Sinha UK; Chen J; Zhang S; Yin C; Wei DD; Hazawa M; Pan H; Lu Z; Wei WQ; Wang MR; Koeffler HP; Lin DC; Jiang YY
Nat Commun; 2024 Mar; 15(1):2484. PubMed ID: 38509096
[TBL] [Abstract][Full Text] [Related]
10. PD-1 regulation in immune homeostasis and immunotherapy.
Gao M; Shi J; Xiao X; Yao Y; Chen X; Wang B; Zhang J
Cancer Lett; 2024 Apr; 588():216726. PubMed ID: 38401888
[TBL] [Abstract][Full Text] [Related]
11. Regulatory mechanisms of PD-1/PD-L1 in cancers.
Lin X; Kang K; Chen P; Zeng Z; Li G; Xiong W; Yi M; Xiang B
Mol Cancer; 2024 May; 23(1):108. PubMed ID: 38762484
[TBL] [Abstract][Full Text] [Related]
12. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.
Yu ZZ; Liu YY; Zhu W; Xiao D; Huang W; Lu SS; Yi H; Zeng T; Feng XP; Yuan L; Qiu JY; Wu D; Wen Q; Zhou JH; Zhuang W; Xiao ZQ
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001908
[TBL] [Abstract][Full Text] [Related]
13. Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation.
Xu X; Xie T; Zhou M; Sun Y; Wang F; Tian Y; Chen Z; Xie Y; Wu R; Cen X; Zhou J; Hou T; Zhang L; Huang C; Zhao Q; Wang D; Xia H
Nat Commun; 2024 May; 15(1):4237. PubMed ID: 38762492
[TBL] [Abstract][Full Text] [Related]
14. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
15. Prolyl isomerase Pin1 sculpts the immune microenvironment of colorectal cancer.
Li Y; Yuan Z; Wang L; Yang J; Pu P; Le Y; Chen X; Wang C; Gao Y; Liu Y; Wang J; Gao X; Li Y; Wang H; Zou C
Cell Signal; 2024 Mar; 115():111041. PubMed ID: 38199598
[TBL] [Abstract][Full Text] [Related]
16. The role of radiotherapy in tumor immunity and the potential of PET/CT in detecting the expression of PD-1/PD-L1.
Shen LF; Fu ZM; Zhou SH
Jpn J Radiol; 2024 Apr; 42(4):347-353. PubMed ID: 37953364
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent
Liu L; Zhang H; Hou J; Zhang Y; Wang L; Wang S; Yao Z; Xie T; Wen X; Xu Q; Dai L; Feng Z; Zhang P; Wu Y; Sun H; Liu J; Yuan H
J Med Chem; 2024 Mar; 67(6):4977-4997. PubMed ID: 38465588
[TBL] [Abstract][Full Text] [Related]
18. FAT4 overexpression promotes antitumor immunity by regulating the β-catenin/STT3/PD-L1 axis in cervical cancer.
Wang D; Wu S; He J; Sun L; Zhu H; Zhang Y; Liu S; Duan X; Wang Y; Xu T
J Exp Clin Cancer Res; 2023 Sep; 42(1):222. PubMed ID: 37658376
[TBL] [Abstract][Full Text] [Related]
19. Construction of stable membranal CMTM6-PD-L1 full-length complex to evaluate the PD-1/PD-L1-CMTM6 interaction and develop anti-tumor anti-CMTM6 nanobody.
Jia XM; Long YR; Yu XL; Chen RQ; Gong LK; Geng Y
Acta Pharmacol Sin; 2023 May; 44(5):1095-1104. PubMed ID: 36418428
[TBL] [Abstract][Full Text] [Related]
20. YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD-L1/VEGFA Axis.
Wen J; Xue L; Wei Y; Liang J; Jia W; Yong T; Chu L; Li H; Han S; Liao J; Chen Z; Liu Y; Liu Q; Ding Z; Liang H; Gan L; Chen X; Huang Z; Zhang B
Adv Sci (Weinh); 2024 Apr; 11(13):e2307242. PubMed ID: 38247171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
